Last reviewed · How we verify

Clomid — Competitive Intelligence Brief

Clomid (clomifene) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Estrogen Agonist/Antagonist. Area: Pain.

marketed Estrogen Agonist/Antagonist 3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase Pain Live · refreshed every 30 min

Target snapshot

Clomid (clomifene) — Sanofi.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Clomid TARGET clomifene Sanofi marketed Estrogen Agonist/Antagonist 3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase 1967-01-01
Osphena OSPEMIFENE Duchesnay marketed Estrogen Agonist/Antagonist [EPC] Estrogen receptor beta 2013-01-01
Fareston TOREMIFENE Kyowa Kirin marketed Estrogen Agonist/Antagonist 5-hydroxytryptamine receptor 6 1997-01-01
Evista RALOXIFENE Eli Lilly marketed Estrogen Agonist/Antagonist estrogen receptors 1997-01-01
Duavee Bazedoxifene Acetate Pfizer Inc. marketed Estrogen agonist/antagonist combination Estrogen receptors (ER) α and β

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Estrogen Agonist/Antagonist class)

  1. Eli Lilly · 1 drug in this class
  2. Kyowa Kirin · 1 drug in this class
  3. Sanofi · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Clomid — Competitive Intelligence Brief. https://druglandscape.com/ci/clomifene. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: